50 related articles for article (PubMed ID: 36371158)
1. Filamin A Is a Prognostic Serum Biomarker for Differentiating Benign Prostatic Hyperplasia from Prostate Cancer in Caucasian and African American Men.
Mahaveer Chand N; Tekumalla PK; Rosenberg MT; Dobi A; Ali A; Miller GM; Aristizabal-Henao JJ; Granger E; Freedland SJ; Kellogg MD; Srivastava S; McLeod DG; Narain NR; Kiebish MA
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398103
[TBL] [Abstract][Full Text] [Related]
2. Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer.
Zhang X; Wang Z; Huang S; He D; Yan W; Zhuang Q; Wang Z; Wang C; Tan Q; Liu Z; Yang T; Liu Y; Ren R; Li J; Butler W; Tang H; Wei GH; Li X; Wu D; Li Z
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 38099500
[TBL] [Abstract][Full Text] [Related]
3. Proteomics of prostate cancer serum and plasma using low and high throughput approaches.
Hamza GM; Raghunathan R; Ashenden S; Zhang B; Miele E; Jarnuczak AF
Clin Proteomics; 2024 Mar; 21(1):21. PubMed ID: 38475692
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for Pre-Treatment Risk Stratification of Prostate Cancer Patients: A Systematic Review.
Sequeira JP; Salta S; Freitas R; López-López R; Díaz-Lagares Á; Henrique R; Jerónimo C
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611041
[TBL] [Abstract][Full Text] [Related]
5. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
6. A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL.
Miyoshi Y; Kawahara T; Uemura H
BMC Cancer; 2022 Nov; 22(1):1169. PubMed ID: 36371158
[TBL] [Abstract][Full Text] [Related]
7. Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naïve prostate cancer.
Miyoshi Y; Uemura H; Umemoto S; Sakamaki K; Taguri M; Suzuki K; Shibata Y; Masumori N; Ichikawa T; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Harada M; Kubota Y
Prostate; 2016 Mar; 76(4):376-82. PubMed ID: 26616365
[TBL] [Abstract][Full Text] [Related]
8. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
9. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
10. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
[TBL] [Abstract][Full Text] [Related]
11. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
12. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
13. Active surveillance in intermediate-risk prostate cancer.
Klotz L
BJU Int; 2020 Mar; 125(3):346-354. PubMed ID: 31647166
[TBL] [Abstract][Full Text] [Related]
14. Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate in Patients with Castration-resistant Prostate Cancer.
Suzuki K; Sakamoto M; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Anticancer Res; 2018 Oct; 38(10):5929-5935. PubMed ID: 30275221
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
